Nephros (NEPH) Stock Price, News & Analysis

Company Overview

Nephros, Inc. (NASDAQ:NEPH) is a medical device company that develops and sells filtration products designed to purify water and other biological fluids. Its technologies are used in healthcare settings and other applications where reducing microbial contamination and impurities is important.

The company’s product portfolio includes ultrafiltration systems and replacement filters for hemodialysis applications, as well as water-filtration products used in hospitals and other healthcare facilities. Nephros also offers filtration solutions intended to support infection-control programs, including products designed for point-of-use water treatment.

Nephros serves healthcare providers, dialysis organizations, hospitals, distributors and commercial customers, primarily through the United States market. Its business has historically focused on applying membrane-filtration technology to improve water quality and support patient-care and facility-management needs.

Key Stats

• Today's Range: $4.12 to $4.12
• 50-Day Range: $3.24 to $4.76
• 52-Week Range: $2.66 to $6.42
• Volume: 306 shs
• Average Volume: 31,232 shs
• Market Capitalization: $44.42 million
• P/E Ratio: 25.56
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Nephros Stock Analysis - MarketRank™

Nephros scored higher than 61% of companies evaluated by MarketBeat, and ranked 357th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Hold

Consensus Rating

Nephros has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Nephros is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Nephros has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 106.67%

Earnings Growth

Earnings for Nephros are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nephros is 26.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nephros is 26.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.

Price to Book Value per Share Ratio

Nephros has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.46% of the float of Nephros has been sold short.

Short Interest Ratio / Days to Cover

Nephros has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nephros has recently increased by 13.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nephros does not currently pay a dividend.

Dividend Growth

Nephros does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Nephros has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Nephros this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Nephros to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nephros insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.70% of the stock of Nephros is held by insiders.

Percentage Held by Institutions

41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:NEPH
• CIK: 1196298
• Web: www.nephros.com
• Phone: (201) 343-5202
• Fax: 201-343-5207
• Employees: 36
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Nephros: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: -2.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.16
• Trailing P/E Ratio: 25.56
• Forward P/E Ratio: 27.27
• P/E Growth: N/A
• Net Income: $1.19 million
• Net Margins: 8.38%
• Pretax Margin: 8.45%
• Return on Equity: 10.60%
• Return on Assets: 8.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: $18.79 million
• Price / Sales: 2.36
• Cash Flow: $0.12 per share
• Price / Cash Flow: 33.24
• Book Value: $0.96 per share
• Price / Book: 4.26

Miscellaneous

• Outstanding Shares: 10,860,000
• Free Float: 10,132,000
• Market Cap: $44.42 million
• Optionable: Not Optionable
• Beta: 1.55